Diagnosis and treatment of heterozygous familial hypercholesterolemia
MP McGowan, SH Hosseini Dehkordi… - Journal of the …, 2019 - Am Heart Assoc
Familial hypercholesterolemia (FH) is a common yet underdiagnosed autosomal dominant
disorder that affects% 1 in 220 individuals globally. 1 FH is characterized by lifelong …
disorder that affects% 1 in 220 individuals globally. 1 FH is characterized by lifelong …
The evolving future of PCSK9 inhibitors
RS Rosenson, RA Hegele, S Fazio… - Journal of the American …, 2018 - jacc.org
Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into
mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies …
mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies …
Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the Writing Committee of the American Society for Apheresis: the …
A Padmanabhan, L Connelly‐Smith… - Journal of clinical …, 2019 - Wiley Online Library
ABSTRACT The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating and categorizing …
Special Issue Writing Committee is charged with reviewing, updating and categorizing …
Guidelines on the Use of therapeutic apheresis in clinical practice–Evidence‐Based approach from the Writing Committee of the American Society for Apheresis: The …
L Connelly‐Smith, CR Alquist, NA Aqui… - Journal of clinical …, 2023 - Wiley Online Library
Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
[HTML][HTML] PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021
M Banach, P Burchardt, K Chlebus… - Archives of Medical …, 2021 - ncbi.nlm.nih.gov
Moreover, over the last few years the approach to treatment of patients with a high
cardiovascular risk has totally changed from treatment aimed at a specific risk factor (ie …
cardiovascular risk has totally changed from treatment aimed at a specific risk factor (ie …
Practical guidance for combination lipid-modifying therapy in high-and very-high-risk patients: a statement from a European Atherosclerosis Society Task Force
Abstract Background and aims This European Atherosclerosis Society (EAS) Task Force
provides practical guidance for combination therapy for elevated low-density lipoprotein …
provides practical guidance for combination therapy for elevated low-density lipoprotein …
Long-term evolocumab in patients with familial hypercholesterolemia
Background Proprotein convertase subtilisin/kexin type 9 inhibitor therapy is a treatment
option for patients with familial hypercholesterolemia (FH) who are unable to reach low …
option for patients with familial hypercholesterolemia (FH) who are unable to reach low …
Guidelines for the diagnosis and treatment of pediatric familial hypercholesterolemia 2022
M Harada-Shiba, A Ohtake, D Sugiyama… - … of atherosclerosis and …, 2023 - jstage.jst.go.jp
As atherosclerosis begins in childhood, early diagnosis and treatment of familial
hypercholesterolemia (FH) is considered necessary. The basic diagnosis of pediatric FH …
hypercholesterolemia (FH) is considered necessary. The basic diagnosis of pediatric FH …
Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial
Abstract Background Homozygous familial hypercholesterolemia (HoFH) is characterized by
extremely elevated low-density lipoprotein–cholesterol (LDL-C) levels and early onset …
extremely elevated low-density lipoprotein–cholesterol (LDL-C) levels and early onset …
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic …
U Landmesser, MJ Chapman, JK Stock… - European heart …, 2018 - academic.oup.com
The first randomized controlled data from cardiovascular outcomes trials with proprotein
convertase subtilisin/kexin type 9 (PCSK9) inhibitors have now been reported. 1, 2 This …
convertase subtilisin/kexin type 9 (PCSK9) inhibitors have now been reported. 1, 2 This …